Trial Profile
O6-alkylguanine-DNA-alkyltransferase modulation study Fotemustine plus Temozolomide phase I/II .
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Jun 2011
Price :
$35
*
At a glance
- Drugs Fotemustine (Primary) ; Temozolomide (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 01 Jun 2011 New trial record